US 12,433,858 B2
Substituted cycloalkanes for managing nephrogenic diabetes insipidus
Jeff Sands, Atlanta, GA (US); Janet Klein, Decatur, GA (US); Ish Khanna, Alpharetta, GA (US); and Sivaram Pillarisetti, Norcross, GA (US)
Assigned to NephroDI Therapeutics, Inc., Seattle, WA (US)
Filed by NephroDI Therapeutics, Inc., Seattle, WA (US)
Filed on Nov. 6, 2023, as Appl. No. 18/502,729.
Application 18/502,729 is a continuation of application No. 17/506,236, filed on Oct. 20, 2021, granted, now 11,844,770.
Application 17/506,236 is a continuation of application No. 16/491,990, granted, now 11,179,354, issued on Nov. 23, 2021, previously published as PCT/US2018/016184, filed on Jan. 31, 2018.
Claims priority of provisional application 62/452,616, filed on Jan. 31, 2017.
Prior Publication US 2024/0139127 A1, May 2, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/19 (2006.01); A61K 9/00 (2006.01); A61K 31/16 (2006.01); A61K 31/194 (2006.01); A61K 33/00 (2006.01); A61P 3/10 (2006.01); C07C 61/00 (2006.01)
CPC A61K 31/16 (2013.01) [A61K 9/0095 (2013.01); A61K 31/194 (2013.01); A61K 33/00 (2013.01); A61P 3/10 (2018.01); A61K 9/0053 (2013.01)] 72 Claims
 
1. A method for treating nephrogenic diabetes insipidus in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable excipient and 1,1′-(dodecane-1,12-diyl)bis(cyclopropane-1-carboxylic acid) of the following structure:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.